CCRN'S 6TH ANNUAL

PFP 2026 CONFERENCE

PARADIGMS IN FAMILY PRACTICE

PERFECTING PRIMARY CARE

RECORDED LIVE ON:

Friday, September 25, 2026
Friday, October 2, 2026
10:00 am - 5:30 pm ET

For program inquiries please contact: **cme@ccrnmd.com**

CCRN
Canadian Collaborative Research Network

PFP 2026 CONFERENCE

VIRTUAL CONFERENCE

Sep 25 & Oct 2, 2026

10:00am - 5:30pm EDT

CONFERENCE OBJECTIVES:

- Apply evidence-based and guideline-centric care for patients in primary care
- Determine and understand patient needs to provide patient-centered care

SEPTEMBER 25, 2026

Time	Session Title	Faculty
10:00am EDT	Welcome & Introduction	
10:05am EDT	Beyond Adolescence: Broadening HPV Vaccination Across Diverse Patient Populations	Dr. Shannon Salvador & Dr. Sheila Wijayasinghe
11:15am EDT	Integrating Sleep into Obesity Care: Practical Strategies for Primary Care	Dr. Jonathan Gabor
12:15pm EDT	Virtual Exhibit Hall & Refreshment Break	
1:00pm EDT	Putting CGM to Work: A Guide for Canadian Clinicians	Dr. Alex Abitbol & Dr. Daniel Ngui
2:10pm EDT	Advanced Topical Therapy Management Options in Atopic Dermatitis	Dr. Farheen Mussani
3:20pm EDT	Prevention and Early Detection to Halt the Slide: Chronic Kidney Disease (CKD) in Diabetes Guideline Updates	Dr. Sheldon Tobe
4:30pm EDT	Reframing Insomnia Management: Evidence-Based Strategies and Clinical Insights for Primary Care	Dr. Serge Lessard
5:30pm EDT	Closing Remarks	

OCTOBER 2, 2026

Time	Session Title	Faculty
10:00am EDT	Welcome & Introduction	
10:05am EDT	Aldosterone Unleashed: Cracking Resistant Hypertension	Dr. Peter Lin
11:15am EDT	Faster Testing for Slower Decline: How to Improve Early Detection and Referrals in Alzheimer's Disease and Why It Matters	Dr. Sharon Cohen
12:15pm EDT	Virtual Exhibit Hall & Refreshment Break	
1:00pm EDT	The First Years Matter: Shaping the Trajectory of T2D Through Early Action	Dr. Jeremy Gilbert
2:10pm EDT	Closing the Prevention Gap in Adult Pneumococcal Disease: Evolving Evidence for Primary Care and Pharmacy Practice	Dr. Alan Kaplan & Sherilyn Houle
3:20pm EDT	The Role of the Primary Care Physician in the Multi-Disciplinary Management of Dyslipidemia in Patients with ASCVD	Dr. Richard Choi
4:30pm EDT	Applying Lipid Guidelines in Primary Care: Challenges and Opportunities	Dr. Milan Gupta & Dr. Robert Hegele
5:30pm EDT	Closing Remarks	

This conference has received unrestricted educational grants and in-kind support from:
Amgen, Arcutis, AstraZeneca, Bayer, Dexcom, Eisai, Eli Lilly and Merck.

CCRN Collaborative CME and Research Network

FRIDAY, SEPTEMBER 25, 2026 - DAY 1

10:05 am - 11:05 am	Beyond Adolescence: Broadening HPV Vaccination Across Diverse Patient Populations	Dr. Shannon Salvador & Dr. Sheila Wijayasinghe

At the conclusion of this activity participants will be able to:

- Describe the prevalence and impact of HPV infection and its associated cancers across diverse patient populations
- Explain the rationale for HPV vaccination in adolescents, including the role of publicly funded programs and current uptake trends in Canada
- Explain the rationale for HPV vaccination beyond adolescence, including benefits for adults, men, and individuals in monogamous relationships
- Apply current HPV vaccination recommendations and interprofessional strategies to build confidence and improve uptake across care settings, including cervical cancer screening visits

11:15 am – 12:15 pm	Integrating Sleep into Obesity Care: Practical Strategies for Primary Care	Dr. Jonathan Gabor

At the conclusion of this activity participants will be able to:

- Describe the relationship between sleep health and obesity
- Examine how sleep fits into the overall patient journey in obesity management.
- Apply practical strategies for integrating sleep considerations into comprehensive obesity

12:15 pm - 1:00 pm	Virtual Exhibit Hall & Refreshment Break

1:00 pm – 2:00 pm	Putting CGM to Work: A Guide for Canadian Clinicians	Dr. Alex Abitbol & Dr. Daniel Ngui

At the conclusion of this activity participants will be able to:

- Describe the current Diabetes Canada guideline recommendations for CGM use in individuals with T1D and T2D
- Identify appropriate candidates for CGM across the spectrum of diabetes types and therapies
- Interpret CGM data to guide individualized pharmacotherapy adjustments.
- Discuss the practical aspects of CGM implementation with patients and the interprofessional team

2:10 pm – 3:10 pm	Advanced Topical Therapy Management Options in Atopic Dermatitis	Dr. Farheen Mussani

At the conclusion of this activity participants will be able to:

- Identify the key clinical features and differential diagnoses of common chronic inflammatory dermatoses - including AD, plaque psoriasis (PsO), and seborrheic dermatitis (seb derm) - in adult and pediatric primary-care patients.
- Evaluate the benefits and limitations of current topical treatment options, including the clinical impact of inappropriate long-term topical corticosteroid use and growing concerns about corticophobia.
- Discuss the clinical impact of formulation considerations in the vehicle aspect of topical agents, particularly with the atopic dermatitis patient in mind
- Assess the evidence from pivotal clinical trials on recently approved advanced non-steroidal targeted topical therapies in AD across adult and pediatric patients.

3:20 pm – 4:20 pm	Prevention and Early Detection to Halt the Slide: Chronic Kidney Disease (CKD) in Diabetes Guideline Updates	Dr. Sheldon Tobe

At the conclusion of this activity participants will be able to:

- Identify screening recommendations for CKD in people with diabetes
- Describe health behaviours and new therapies to prevent onset and progression of diabetic nephropathy toward end stage kidney disease
- Integrate new Diabetes Canada recommendations into clinical practice

4:30 pm – 5:30 pm	Reframing Insomnia Management: Evidence-Based Strategies and Clinical Insights for Primary Care	Dr. Serge Lessard

At the conclusion of this activity participants will be able to:

- Apply evidence-based assessment tools to evaluate patients with insomnia.
- Analyze the benefits and limitations of non-pharmacological interventions as first-linetherapy.
- Evaluate pharmacological treatment options based on patient-specific factors.
- Create safe and effective transition strategies between different classes of insomnia medications, including dual orexin receptor antagonists (DORAs).
- Formulate comprehensive management plans integrating pharmacological and non-pharmacological interventions.

FRIDAY, OCTOBER 2, 2026 - DAY 2

10:05 am - 11:05 am	Aldosterone Unleashed: Cracking Resistant Hypertension	Dr. Peter Lin

At the conclusion of this activity participants will be able to:

- Explain how aldosterone contributes to uncontrolled and resistant hypertension
- Assess clinical evidence for established and novel aldosterone-targeted therapies
- Implement streamlined approaches to optimize hypertension management

11:15 am – 12:15 pm	Faster Testing for Slower Decline: How to Improve Early Detection and Referrals in Alzheimer's Disease and Why It Matters	Dr. Sharon Cohen

At the conclusion of this activity participants will be able to:

- Recognize cognitive, behavioural, and functional changes that warrant a dementia work-up
- Describe the value of diagnosing Alzheimer's disease as early as possible
- Answer patients' questions about blood-based biomarkers and disease-modifying therapy (DMT)
- Identify patients who should be fast-tracked for referral due to urgent concerns or eligibility for DMT

12:15 pm - 1:00 pm	Virtual Exhibit Hall & Refreshment Break

1:00 pm – 2:00 pm	The First Years Matter: Shaping the Trajectory of T2D Through Early Action	Dr. Jeremy Gilbert

At the conclusion of this activity participants will be able to:

- Describe the importance of early treatment optimization in altering the long-term trajectory of T2D.
- Identify patient factors that influence early treatment decisions in T2D.
- Apply current evidence and guideline recommendations to individualize treatment strategies early in the T2D disease course.
- Evaluate the evolving role of oral and injectable incretin-based therapies in the T2D continuum.

2:10 pm – 3:10 pm	Closing the Prevention Gap in Adult Pneumococcal Disease: Evolving Evidence for Primary Care and Pharmacy Practice	Dr. Alan Kaplan & Sherilyn Houle

At the conclusion of this activity participants will be able to:

- Describe the burden of adult pneumococcal disease in Canada, including the role of the aging immune system
- Recognize opportunities for primary care physicians and pharmacists to collaborate to improve disease prevention in adults at risk for invasive pneumococcal disease (IPD)
- Apply current Canadian pneumococcal vaccination recommendations to adult patient care

3:20 pm – 4:20 pm	The Role of the Primary Care Physician in the Multi-Disciplinary Management of Dyslipidemia in Patients with ASCVD	Dr. Richard Choi

At the conclusion of this activity participants will be able to:

- Identify patients who would derive the largest benefit from additional therapy beyond statins to reduce CV risk
- Apply the evidence from clinical trials, guideline recommendations and real-world data for PCSK9 inhibitor therapy to routine clinical decision making for ASCVD patients
- Recognize the role of the primary care physician through case-based learning in achieving guideline-recommended LDL-C threshold recommendations in ASCVD patients, including those at highest-risk, to reduce recurrent events

4:30 pm – 5:30 pm	Applying Lipid Guidelines in Primary Care: Challenges and Opportunities	Dr. Milan Gupta & Dr. Robert Hegele

At the conclusion of this activity participants will be able to:

- Identify challenges in applying lipid guidelines in primary care
- Summarize new evidence that may influence the future evolution of lipid guidelines
- Develop strategies incorporating recent international guidelines for best practices in lipid management